https://www.eventura.us/live-webinars/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-ba-be-studies2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/preparing-a-510-k-premarket-notification2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/chatgpt-and-ai-powered-project-management-revolutionize-your-projects-now2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/pre-inspection-self-audits-moving-beyond-checklists-to-identify-real-system-risks2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/validating-ai-use-in-quality-systems-practical-csv-and-csa-approaches-for-fda-inspection-readiness2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/inspection-readiness-defending-your-use-of-ai-to-fda-and-auditors2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/deviation-backlog-reduction-balancing-investigation-depth-closure-speed-and-justifiable-decisions2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/advanced-therapy-gmp-release-and-chain-of-identity-controls2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/ai-in-gmp-what-the-fda-is-already-expecting-before-you-ask2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/root-cause-analysis-for-gmp-investigations-identifying-systemic-failures-and-building-effective-capa2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/ai-assisted-post-market-surveillance-and-signal-detection-what-regulators-will-still-expect-humans-to-defend2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/otc-monograph-reform-and-omufa-ii-what-fda-s-modernized-otc-framework-means-for-manufacturers2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/iq-oq-pq-sufficient-validation-evidence2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/qmsr-device-records-structuring-ddf-mdf-and-related-relationships-for-inspection-readiness2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/annex-22-and-ai-governance-for-gmp-human-review-model-monitoring-and-change-control2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/ai-in-drug-discovery-aligning-with-fda-s-latest-risk-based-framework2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/risk-management-for-ai-in-medical-devices-insights-from-fda-s-life-cycle-management-draft-guidance2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/us-fda-s-ai-framework-for-medical-devices2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/ai-errors-may-be-impossible-to-eliminate-what-that-means-for-its-use-in-the-fda2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/the-first-fda-warning-letter-on-ai-what-it-means-for-your-quality-system2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/laboratory-developed-tests-ldt-the-impact-of-the-final-rule2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/nitrosamines-impurities-management2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/post-csa-transition-key-challenges-and-leveraging-opportunities2026-07-28T16:40:10+00:000.8https://www.eventura.us/live-webinars/the-fda-s-qualification-of-medical-device-development-tools-mddt-program2026-07-28T16:40:10+00:000.8